PRL-3, in particular, has been identified as a potential biomarker of cancer progression and metastasis in colorectal [1, 2], gastric [3], ovarian [4], breast [5], brain [6], and prostate [7] cancers, as well as melanoma [8, 9], and leukemias [10, 11]. The gene discussed is PTP4A3; the disease is cancer.